1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

AstraZeneca Finds Two More Potential Partners For Imfinzi

Combo Data At ESMO Supports Use With CD73 And NGK2A Inhibitors

 
• By Alaric DeArment

Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.

Lung Cancer
AstraZeneca reported results at ESMO on Imfinzi combined with CD73 inhibitor oleclumab and NGK2A inhibitor monalizumab • Source: Shutterstock

AstraZeneca PLC appears to have found two novel immuno-oncology partners that can improve outcomes when combined with its PD-L1 checkpoint inhibitor Imfinzi (durvalumab) without adding very much to toxicity, according to early data presented at the European Society for Medical Oncology meeting. It’s a positive step for a company that has contended with several setbacks in establishing Imfinzi in combination regimens, and AstraZeneca could see an even greater victory from a Phase III trial combining Imfinzi with chemoradiation therapy expected to read out later this year

In the Phase II COAST trial presented at ESMO on 17 September, Imfinzi combined with either the CD73-targeting oleclumab or...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

More from Therapy Areas

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.